On the Cutting Edge of Migraine Medicine

Mind+ Neurology Leads the Way in Groundbreaking Episodic Migraine Clinical Trial for AstraZeneca

Mind+ Neurology, a headache and migraine clinic with locations in Mequon and Appleton, is proudly announcing its participation in a cutting-edge Episodic Migraine clinical trial in partnership with AstraZeneca. Notably, Mind+ Neurology has achieved a historic milestone by administering the study drug to the first patient in the world, solidifying its reputation as a leader in headache and migraine treatment. It is also the only site in Wisconsin selected to participate in this groundbreaking research. This clinical trial provides an opportunity for eligible participants to contribute to medical advancements while receiving expert care at no cost.

Since opening its doors in October 2022, Mind+ Neurology has been dedicated to transforming the treatment of headache and migraine disorders. The clinic, founded by Dr. Aaron H. Bubolz, DO, a board-certified neurologist specializing in headache and migraine medicine, was designed specifically to address the needs of migraine sufferers. With a team boasting over 40 years of combined experience, Mind+ Neurology offers unparalleled expertise and innovative care, including the nation’s only Headache Urgent Care, providing immediate rescue relief for severe migraines.

About the Clinical Trial

The new study focuses on episodic migraine which is characterized by 4 to 14 migraine days per month. Mind+ Neurology is currently enrolling participants for AstraZeneca’s study, which aims to explore new treatment options for individuals suffering from this debilitating condition.

Eligibility Criteria:

• Must experience 4 or more headache days per month.
• If currently on preventive migraine treatment, must gradually discontinue use.
• Must complete an in-person screening visit.
• Required to maintain a 30-day Electronic Diary tracking migraine occurrences.

Study Details:

• Duration: 12 weeks.
• Structure: 6 biweekly office visits to the Mequon, WI clinic location.
• Randomization: Participants will be randomly assigned, with a possibility of receiving a placebo.
• Cost: No cost to participate.
• Compensation: Participants will receive approximately $1,200 over the course of the study, with payments distributed after each visit on a reloadable Visa Card.
• Voluntary Participation: Participants may withdraw at any time.

For more information or to determine eligibility, go to: https://www.mindplusclinic.com/clinical-trial/ .